Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
For patients with resected pancreatic cancer who received neoadjuvant gemcitabine + Abraxane, would you switch to gemcitabine + capecitabine to complete 6 months of peri-operative therapy?
Related Questions
Is the increase in RFS seen with adjuvant atezo/bev in IMbrave050 enough to change practice in resected HCC?
Would you recommend adjuvant capecitabine and radiation in addition to adjuvant FOLFOX for a patient with resected pT3N2 rectosigmoid adenocarcinoma with other high-risk pathologic features?
Which adjuvant chemotherapy would you offer to a MSI high pancreatic cancer patient after Whipple?
How would you treat a synchronous low rectal adenocarcinoma and anal squamous cell carcinoma with involved pelvic and inguinal nodes?
How would you approach a gastric GIST with R1 resection?
How long do you treat with immunotherapy patients with MSI-high T4B initially unresectable colon adenocarcinoma?
Would you offer chemotherapy to an elderly patient with MSI-H stage 3 colon cancer who cannot tolerate oxaliplatin?
How do you approach a low grade intra-cholecystic papillary neoplasm of the gallbladder without invasive component and reported surgical pathology with negative margins ?
Is there data to support a 3 weeks regimen of panitumumab with maintenance capecitabine in colon cancer?
Would you offer adjuvant chemotherapy after SBRT for biopsy proven sub centimeter metastatic pulmonary nodule from rectal cancer?